Praxis Precision Medicines (PRAX) Projected to Post Earnings on Tuesday

Praxis Precision Medicines (NASDAQ:PRAX) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($2.76) per share and revenue of $0.36 million for the quarter.

Praxis Precision Medicines Price Performance

Shares of PRAX opened at $66.71 on Tuesday. The company has a market cap of $1.24 billion, a PE ratio of -6.48 and a beta of 2.65. The firm has a 50-day moving average of $77.30 and a 200-day moving average of $69.56. Praxis Precision Medicines has a one year low of $33.01 and a one year high of $91.83.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PRAX shares. Truist Financial boosted their price target on Praxis Precision Medicines from $150.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st. Needham & Company LLC restated a “buy” rating and issued a $150.00 price target on shares of Praxis Precision Medicines in a research note on Monday, February 10th. Oppenheimer lifted their price objective on shares of Praxis Precision Medicines from $143.00 to $163.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Praxis Precision Medicines in a report on Tuesday, February 11th. They set a “buy” rating and a $111.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Praxis Precision Medicines has a consensus rating of “Moderate Buy” and an average price target of $145.20.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.